Skip to main content

Recursion Pharmaceuticals Inc Cl A(RXRX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low3.46
Day High3.57
Open:3.50
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Tipranks
Analysts Offer Insights on Healthcare Companies: Labcorp Holdings (LH), Recursion Pharmaceuticals (RXRX) and Johnson & Johnson (JNJ)
GlobeNewswire
Recursion to Participate in Upcoming Investor Conferences
Motley Fool
1 Beaten-Down AI Stock to Buy and 1 to Avoid
GlobeNewswire
Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform
Motley Fool
2 AI Healthcare Stocks to Buy Right Now
Tipranks
Recursion Pharmaceuticals Names New Chief Medical Officer
GlobeNewswire
Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer
Motley Fool
Prediction: The "Trough of Disillusionment" Will Create the Best Buying Opportunity for Artificial Intelligence (AI) Stocks in 2026
Motley Fool
Want $1 Million in Retirement? Invest $10,000 in These 2 AI Stocks and Hold for 10 Years.
Motley Fool
Can This AI Stock Bounce Back in 2026?
Tipranks
Recursion Pharmaceuticals’ Earnings Call Highlights AI Momentum
GlobeNewswire
PacBio Announces the Appointment of Chris Gibson to the Board of Directors
Zacks Investment Research
Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down
Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down
Tipranks
Analysts Offer Insights on Healthcare Companies: Celldex (CLDX) and Recursion Pharmaceuticals (RXRX)
Tipranks
Analysts Offer Insights on Healthcare Companies: Recursion Pharmaceuticals (RXRX) and Penumbra (PEN)
Zacks Investment Research
Catalyst Pharmaceuticals Q4 Earnings Beat, Firdapse Revenues Rise Y/Y
Catalyst Pharmaceuticals Q4 Earnings Beat, Firdapse Revenues Rise Y/Y
Zacks Investment Research
ACAD Q4 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth
ACAD Q4 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth
Tipranks
Recursion Highlights AI Validation, Extends Cash Runway to 2028
Motley Fool
Recursion (RXRX) Q4 2025 Earnings Call Transcript
Zacks Investment Research
RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up
RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up
GlobeNewswire
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
GlobeNewswire
Recursion To Be Featured in HighRes’ Lightning Talk at NVIDIA GTC
GlobeNewswire
Recursion to Participate in Upcoming Investor Conferences
Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
MarketBeat
NVIDIA’s 13F Bombshell: A New AI Power Trio Emerges
MarketBeat.com
GlobeNewswire
Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25
Zacks Investment Research
Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards?
Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards?
GlobeNewswire
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
Motley Fool
This $4 Stock Could Be Your Ticket to Millionaire Status
Tipranks
Recursion’s REC-4881 Cancer Trial Terminated: Reading the Signals for RXRX Investors
Newswire.ca
AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift
Motley Fool
Forget 2025: These 2 Growth Stocks Could Soar in 2026

Profile

Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering. Recursion Pharmaceuticals Inc. is based in SALT LAKE CITY.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.